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Abstract
Aim: The aim was to investigate the association between human insulin and cancer incidence and mortality in Chinese
patients with type 2 diabetes.
Methods: We recruited 8,774 insulin-naı¨ve diabetes patients from the Shanghai Diabetes Registry (SDR). The follow-up rate
was 85.4%. All subjects were divided into the insulin use cohort (n = 3,639) and the non-insulin use cohort (n = 5,135). The
primary outcome was the first diagnosis of any cancer. The secondary outcome was all-cause mortality. Cox proportional
hazards model was used to estimate the relative risk (RR) of cancer and mortality.
Results: We observed 98 cancer events in the insulin use cohort and 170 in the non-insulin use cohort. Cancer incidence
rates were 78.6 and 74.3 per 10,000 patients per year in the insulin users and the non-insulin users, respectively. No
significant difference in cancer risk was observed between the two cohorts (adjusted RR = 1.20, 95% CI 0.89–1.62, P = 0.228).
Regarding site-specific cancers, only the risk of liver cancer was significantly higher in the insulin users compared to that in
the non-insulin users (adjusted RR = 2.84, 95% CI 1.12–7.17, P = 0.028). The risks of overall mortality (adjusted RR = 1.89, 95%
CI 1.47–2.43, P,0.0001) and death from cancer (adjusted RR = 2.16, 95% CI 1.39–3.35, P = 0.001) were all significantly higher
in the insulin users than in the non-insulin users.
Conclusion: There was no excess risk of overall cancer in patients with type 2 diabetes who were treated with human
insulin. However, a significantly higher risk of liver cancer was found in these patients. Moreover, insulin users showed
higher risks of overall and cancer mortality. Considering that individuals treated with insulin were more likely to be
advanced diabetic patients, caution should be used in interpreting these results.
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Introduction
Diabetes and anti-diabetic therapy were both possibly related to
cancer morbidity and mortality. Several cohort studies have
strongly suggested that the incidence of some types of cancer and
mortality is higher in patients with diabetes, predominantly type 2
diabetes [1]. There is also evidence suggests that several
hypoglycemic medications are associated with either an increased
or a reduced risk of cancer [2]. Insulin is one of the most
commonly prescribed medications, and the interest in its role on
cancer risk in diabetic patients has increased recently. Some results
showed that insulin was associated with an increased cancer risk
[3], [4], [5], [6], [7], while others suggested that insulin did not
play a role in cancer development [8]. Similarly, there is an
inconsistency with regard to the safety of insulin therapy in
Chinese diabetic population. Yang et al. analyzed the database
from the Hong Kong Diabetic Registry and reported that insulin
was related to lower incidence of cancer [9]. Chang et al. reported
PLOS ONE | www.plosone.org 1 January 2013 | Volume 8 | Issue 1 | e53411
that insulin glargine did not increase the overall cancer incidence
when compared with human insulin in the Taiwanese population
[10], and Tseng et al. found that insulin use did not increase colon
cancer mortality [11]. However, studies regarding the relationship
between insulin and cancer incidence and mortality in the
population from Mainland China are still lacking. During the
past few decades, human insulin has been widely used in diabetic
population from Mainland China. Therefore, the primary
objective of the present study was to survey the overall and site-
specific cancer risk in Chinese patients with type 2 diabetes who
were treated with human insulin. Our secondary objective was to
examine the relationship between insulin use and mortality in
patients with type 2 diabetes.
Methods
Ethics Statement
This study was approved by the institutional review board of
Shanghai Jiao Tong University Affiliated Sixth People’s Hospital
in accordance with the principles of the Helsinki Declaration II.
Written informed consent was obtained from each participant.
Research Design
This was a population-based, observational cohort study
performed by using the Shanghai Diabetes Registry (SDR)
database, which was established in December 2001 at the
Shanghai Jiao Tong University Affiliated Sixth People’s Hospital,
the Shanghai Clinical Center for Diabetes. This computerized
database was set up with the aim of evaluating the outcome of
Chinese patients with diabetes. Outpatients and hospitalized
patients, who were willing to attend this follow-up program, were
asked to register in our center. After filling in the registration
details, each outpatient underwent a comprehensive assessment of
diabetic complications. The data for the discharged patients were
collected during hospitalization. Each enrolled patient was given a
unique registry number and invited to attend follow-up at the
center until the time of death. During follow-up, glucose-lowering
agents were prescribed by trained clinical physicians based on
each patient’s glucose levels. Detailed information of each subject,
including demographics, diagnoses, laboratory measurements and
drug prescriptions, were recorded by trained diabetic nurses.
Cohort Definition
Patients who were insulin naı¨ve and without a diagnosis of
cancer were eligible for analysis. Those patients who initiated
insulin therapy (new users) were defined as insulin users and those
who received OAD (new and previous users) but no insulin
therapy were defined as non-insulin users.
Outcomes
The primary outcome was the first recorded diagnosis of any
cancer. The secondary outcome was all-cause mortality. The
identification of cancer events, sites, and death was performed
according to the International Classification of Diseases, 9th and
10th revisions (ICD-9, ICD-10). The information of all cancer
events, cancer sites, and causes of death was retrieved from
Shanghai Municipal Center for Disease Control and Prevention.
Patients Screening
A total of 12,973 Shanghai residents with diabetes enrolled in
our registry from December 1, 2001 to July 31, 2010 (Figure 1).
There were 2696 patients excluded in the present study: including
181 patients with type 1 diabetes and 164 patients aged under 30
years; 516 patients diagnosed with cancer at or before enrollment
and 659 patients treated with insulin before enrollment; 32 and 16
patients who were diagnosed with cancer before insulin or OAD
initial use but after enrollment, respectively; 213 subjects treated
with insulin or OAD for less than 6 months; another 915 with
incomplete data. Among the remaining 10,277 patients, 1,503
were lost to follow up. The follow-up rate was 85.4%. Finally,
8,774 patients were eligible for the present analysis, including
3,639 patients in the insulin user cohort and 5,135 in the non-
insulin user cohort.
Follow-up Time
In the insulin use cohort, baseline was defined as the date of
initiating insulin use. In the non-insulin use cohort, baseline was
defined as the date of enrollment (previous users) or the date of
OAD initially use (new users). The follow-up time for cancer
outcome was calculated from baseline to the earliest date of the
first cancer diagnosis, date of death if no cancer was diagnosed, or
the end date of the study (July 31, 2011) if no cancer was
diagnosed nor had the patient died. The follow-up time for
mortality outcome was calculated from baseline to the date of any
cause of death, or the end date of the study.
Data use from the SDR
We extracted data from the computerized SDR database. The
available data in the study included age, sex, body mass index
(BMI), diabetes duration, waist circumference, hypertension
history, smoking and drinking status, systolic blood pressure
(SBP), the lipid spectrum (total cholesterol [TC], triglyceride [TG],
high-density lipoprotein [HDL], and low-density lipoprotein
[LDL]), glycosylated hemoglobin (HbA1c), fasting C-peptide,
microvascular complications (nephropathy and retinopathy), and
macrovascular complications (coronary artery disease, cerebro-
vascular disease, and peripheral artery disease).
Statistical Analyses
All continuous variables were checked for normal distribution
by the Kolmogorov–Smirnov normality test. Normally distributed
variables are expressed as mean 6 standard deviation, while
skewed variables are expressed as the median (interquartile range,
IQR). The unpaired two-tailed Student’s t-tests and Mann-
Whitney U-tests were applied to examine difference between the
two groups for normally and non-normally distributed parameters,
respectively. The chi-square test was used to compare categorical
variables between two groups. Kaplan–Meier survival curves were
calculated for both cohorts and compared using the log-rank test.
The Cox regression model was then conducted to adjust for
potential confounders, including age, sex, diabetes duration,
smoking status, HbA1c, macrovascular disease, and the use of
oral glucose-lowering agents (including metformin, sulfonylureas
and acarbose). We considered P values of ,0.05 (2-tailed tests) to
be statistically significant. Statistical analysis was performed using
SPSS 17.0 (SPSS, Chicago, IL, USA).
Results
Baseline Characteristics
Clinical characteristics of the two inception cohorts at baseline
are shown in Table 1. Compared to the non-insulin use cohort, the
insulin use cohort showed older age and a lower percentage of
men. The insulin users exhibited a longer median diabetic
duration and a lower median level of fasting C-peptide than the
non-users. Greater percentages of patients with a history of
hypertension, microvascular as well as macrovascular complica-
tions were detected in the insulin use cohort. Those patients
Insulin Treatment, Cancer and Mortality
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treated with insulin had lower frequencies of metformin and
sulfonylureas use. Glucose control was worse in the insulin use
cohort than in the non-insulin use cohort.
Incidence Rate of Cancer
The overall mean follow-up time was 48.7 months (median,
46.1 mouths; maximum, 115.3 months) for cancer incidence and
49.2 months (median, 46.5 mouths; maximum, 115.3 mouths) for
mortality. The median time under observation for cancer was
longer in the non-insulin use cohort than in the insulin use cohort
(50.7 months vs. 40.4 months, p,0.0001). We observed 98 cancer
events with an incidence rate of 76.8 per 10,000 patients per year
in the insulin users and 170 cancer events with an incidence rate of
74.3 per 10,000 patients per year in the non-insulin users. As for
site-specific cancers, liver cancer (11.9 per 10,000 patients per
year) showed the highest incidence rate in the insulin use cohort,
while lung cancer (12.0 per 10,000 patients per year) exhibited the
highest incidence rate in the non-insulin use cohort.
As shown in Table 3, no significant difference was detected for
overall cancer risk between the insulin users and the non-insulin
users (crude RR = 1.05, 95% CI 0.82–1.35, P= 0.695; fully
adjusted: RR = 1.20, 95% CI 0.89–1.62, P= 0.228, Figure 2A).
Regarding site-specific cancers, only liver cancer risk was higher in
the insulin users compared with the non-insulin users (fully
Figure 1. Flow chart of the type 2 diabetic patients in the study.
doi:10.1371/journal.pone.0053411.g001
Insulin Treatment, Cancer and Mortality
PLOS ONE | www.plosone.org 3 January 2013 | Volume 8 | Issue 1 | e53411
adjusted RR = 2.84, 95% CI 1.12–7.17, P= 0.028). Pancreatic
cancer risk was higher in the insulin users compared with the non-
insulin users in the crude model (RR = 2.55, 95% CI 1.04–6.26,
P= 0.042), but was not statistically significant after fully adjusted
(RR = 2.73, 95% CI 0.93–7.99, P= 0.067).
Incidence Rate of Mortality
At the end of the study, a total of 248 death events occurred in
the insulin use cohort and 227 occurred in the non-insulin use
cohort, with an incidence rate of 193.7 per 10,000 patients per
year and 99.0 per 10,000 patients per year, respectively (Table 2).
Higher overall mortality risk was observed in the patients under
insulin therapy (fully adjusted RR = 1.89, 95% CI 1.47–2.43,
P,0.0001, Table 4, Figure 2B). For the causes of mortality, risks of
death from cancer (fully adjusted RR = 2.16, 95% CI 1.39–3.35,
P= 0.001, Table 2, Figure 2C) and from pneumonia and
respiratory system diseases (fully adjusted RR = 2.31, 95% CI
1.27–4.18, P= 0.006) were significantly higher in the insulin users
compared with the non-insulin users. Although the incidence rate
of death from cardiovascular disease was higher in the insulin users
(32.8 per 10,000 patients per year) than in the non-insulin users
(14.0 per 10,000 patients per year), no significant difference
between the two cohorts was found for the risk of death from
cardiovascular disease (fully adjusted RR = 1.83, 95% CI 0.91–
3.68, P= 0.001). The risks of death from cerebrovascular disease
(fully adjusted RR = 0.83, 95% CI 0.43–1.62, P= 0.593) and renal
failure (fully adjusted RR = 2.25, 95% CI 0.63–7.95, P= 0.210)
were not significantly different between the two cohorts.
Discussion
Insulin use and Cancer Risk
The present study showed that insulin use was not significantly
associated with overall cancer risk in Chinese patients with type 2
diabetes. The result is consistent with the ORIGIN trial [12]
which reported that insulin glargine had a neutral effect on
cancers. Recently, a nationwide cohort study in Denmark [13]
reported that use of human insulin was associated with a
significantly higher rate ratio (RR = 1.40, 95% CI 1.33–1.48)
compared with unexposed individuals. But the highest RR of
cancer was found during the first 30 days of treatment, and
declined rapidly, reaching a RR of cancer comparable to
Table 1. Comparison of characteristics between insulin users and non-insulin users.
Characteristics Insulin users n=3639 Non-Insulin users n =5135 P
Men, no. (%) 1874 (51.5) 2795(54.4) 0.007
Age at baseline, year 62.2 (18.0) 61.0 (17.0) ,0.0001
Duration of diabetes, years 9.1 (9.7) 4.0 (7.7) ,0.0001
Smoking status, no. (%) 0.695
Ex-smoker 140 (3.8) 202(4.0)
Current smoker 697 (19.2) 1019 (19.8)
Non-smoker 2802 (77.0) 3914 (76.2)
Alcohol drinking status, no. (%) 0.238
Ex-drinker 316 (8.7) 494 (9.6)
Current drinker 95 (2.6) 119 (2.3)
Non-drinker 3228 (88.7) 4522 (88.1)
History of hypertension, no. (%) 1804(49.6) 2426 (47.2) 0.031
SBP, mmHg 135.0 (30.0) 135.0 (26.0) 0.422
BMI, kg/m2 24.1 (4.3) 24.2 (4.2) 0.351
Waist circumference, cm
Man 89.0 (12.0) 89.0 (11.0) 0.067
Woman 86.0 (13.0) 85.0 (12.0) ,0.0001
HbA1c, % 8.6 (3.5) 7.2 (2.2) ,0.0001
Fasting C-peptide, ng/ml 1.9 (1.5) 2.1 (1.6) ,0.0001
TC, mmol/l 4.9 (1.3) 4.9 (1.3) 0.133
TG, mmol/l 1.4 (1.0) 1.5 (1.0) 0.573
HDL, mmol/l 1.2 (0.4) 1.2 (0.4) 0.235
LDL, mmol/l 3.0 (1.3) 3.1 (1.1) 0.401
Microvascular complication, no. (%) 808 (22.2) 900 (17.5) ,0.0001
Macrovascular complication, no. (%) 917 (25.2) 752 (14.6) ,0.0001
Metformin, no. (%) 1310 (36.0) 2286 (44.5) ,0.0001
Sulfonylureas, no. (%) 1480 (40.7) 3050 (59.4) ,0.0001
Acarbose, no. (%) 2484 (68.3) 3585 (69.8) 0.120
Data are presented as median (inter-quartile range) for non-normally distributed variables and no. (%) for categorical variables, unless specified otherwise. The t-test was
used for variables with normal distribution, the Wilcoxon signed ranks test for non-normal distributed variables, and the x2 test for proportions. SBP: systolic blood
pressure; BMI: body mass index; TC: total cholesterol; TG: triglycerides; HDL: high-density lipoprotein; LDL: low density lipoprotein.
doi:10.1371/journal.pone.0053411.t001
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Figure 2. Kaplan–Meier curves of the proportion of participants with events over time.
doi:10.1371/journal.pone.0053411.g002
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unexposed individuals after 6–12 months of therapy. Therefore,
the authors suggested that the relation between higher cancer risk
and human insulin use were most likely to be due to confounding
and/or surveillance bias rather than causal [13].
For site-specific cancers, we found that use of insulin was only
significantly associated with a higher risk of liver cancer after full
adjustment. This finding was in accordance with several previous
studies. Chang et al [14] found that newly diagnosed diabetic
patients treated with insulin were more likely to develop solid
cancers of the liver, colorectal, pancreas, lung, and stomach than
those treated without insulin. Lai SW, et al [15] found that
comorbidity with cirrhosis and/or hepatitis appeared to be
Table 2. Crude incidence rate of cancer and mortality among insulin users vs. non-insulin users.
Outcomes Insulin users Non-insulin users
No of case (%)
Incidence rate per 10,000
patients per year No of Case (%)
Incidence rate per 10,000
patients per year
Cancer
Follow-up time, months (median, IQR) 40.4 (27.8) 50.7 (42.3)
Observed person-years 12759.0 22884.7
Overall cancer 98 (100.0) 76.8 170 (100.0) 74.3
Breast cancer (women) 4 (4.1) 3.2 14 (8.2) 6.2
Lung cancer 13 (13.3) 10.3 27 (15.9) 12.0
Colorectal Cancer 13 (13.3) 10.3 18 (10.6) 8.0
Gastric cancer 10 (10.2) 8.0 26 (15.3) 11.6
Liver cancer 15 (15.3) 11.9 12 (7.1) 5.4
Pancreatic cancer 12 (12.2) 9.6 8 (4.7) 3.6
Prostate cancer (men) 7 (7.1) 5.6 9 (5.3) 4.1
Mortality
Follow-up time, months (median, IQR) 40.6 (27.8) 51.2 (42.3)
Observed person-years 12804.2 22930.5
Overall mortality 248 (100.0) 193.7 227 99.0
Death from cancer 57 (23.0) 44.8 71 (31.3) 31.0
Death from cardiovascular disease 42 (16.9) 32.8 32 (14.1) 14.0
Death from cerebrovascular disease 32 (12.9) 25.0 37 (16.3) 16.1
Death from pneumonia and respiratory failure 58 (23.4) 45.3 38 (16.7) 16.6
Death from renal failure 15 (6.0) 11.7 7 (3.1) 3.1
doi:10.1371/journal.pone.0053411.t002
Table 3. Intermediate and final models with RRs (95% CIs) for insulin use (reference group: non-insulin use) for cancer events.
Cancer Unadjusted
Adjusted for age
and sex
Adjusted for age,
sex, and smoking
status
Adjusted for age,
sex, smoking
status, and
diabetes
duration
Adjusted for age,
sex, smoking
status, diabetes
duration,
macrovascular,
and HbA1c
Adjusted for age,
sex, smoking
status, diabetes
duration,
macrovascular,
HbA1c. and
concomitant oral
glucose lowering
agents*
Overall cancer 1.05 (0.82–1.35) 0.99 (0.77–1.28) 0.99 (0.77–1.27) 1.04 (0.80–1.35) 1.20 (0.89–1.61) 1.20 (0.89–1.62)
Breast cancer (women) 0.45 (0.15–1.37) 0.41 (0.14–1.25) 0.41 (0.14–1.25) 0.35 (0.11–1.12) 0.35 (0.10–1.18) 0.33 (0.10–1.13)
Lung cancer 0.87 (0.45–1.69) 0.80 (0.41–1.57) 0.80 (0.41–1.56) 0.97 (0.49–1.93) 0.97 (0.45–2.07) 1.00 (0.46–2.17)
Colorectal Cancer 1.49 (0.72–3.09) 1.38 (0.66–2.88) 1.37 (0.65–2.85) 1.32 (0.61–2.83) 1.28 (0.53–3.12) 1.25 (0.50–3.12)
Gastric cancer 0.70 (0.34–1.47) 0.66 (0.31–1.38) 0.65 (0.31–1.36) 0.59 (0.27–1.27) 0.57 (0.25–1.31) 0.53 (0.23–1.23)
Liver cancer 2.03 (0.95–4.35) 1.91 (0.89–4.12) 1.92 (0.89–4.13) 1.93 (0.87–4.28) 2.88 (1.16–7.16) 2.84 (1.12–7.17)
Pancreatic cancer 2.55 (1.04–6.26) 2.26 (0.92–5.58) 2.27 (0.92–5.60) 2.54 (1.00–6.45) 2.55 (0.88–7.36) 2.73 (0.93–7.99)
Prostate cancer (men) 1.37 (0.47–4.00) 1.34 (0.45–3.93) 1.36 (0.46–4.01) 1.70 (0.56–5.12) 1.97 (0.60–6.45) 2.07 (0.62–6.95)
*Oral glucose-lowering agents, including metformin, sulfonylureas, and acarbose.
doi:10.1371/journal.pone.0053411.t003
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associated with a very high increased risk of developing liver
cancer among diabetic patients. They also found that liver cancer
risk reduced more significantly in those diabetic patients treated
with metformin or thiazolidinediones but not insulin. In terms of
mechanisms of the link between insulin use and an increased risk
of liver cancer, Heuson et al. suggested that liver cells are exposed
to higher insulin concentrations than other tissues due to the portal
circulation, a condition that is exacerbated in individuals with
insulin-resistant hyperinsulinemic type 2 diabetes [16]. However,
the liver is exposed to the same insulin levels as the other organs in
insulin-deficient diabetic patients who were treated with exoge-
nous insulin [17]. Thus, this assumption might only explain the
relation between insulin use and higher risks of liver cancer in
those patients with insulin resistance, but not insulin-deficient
patients. Nonetheless, there is also evidence suggested that both
mean and total volumes of hepatocellular tumors in the insulin-
deficient mice were more than two-fold larger than those in the
normal controls, with no significant difference in tumor number.
The tumors in insulin-deficient mice showed a significantly lower
frequency of apoptosis but no alteration in cell proliferation [18].
Therefore, the exact mechanisms underlying the association
between a high risk of liver cancer and insulin use in type 2
diabetes are still unclear and further clinical and laboratory studies
are required to clarify these mechanisms.
Insulin use and Mortality Risk
Several studies found that insulin use was associated with risk for
mortality in type 2 diabetes [3], [19–20]. Some of these studies
compared the effects of insulin with metformin [3], while others
examined the safety of insulin by comparison of human insulin-
treated diabetic patients with non-diabetic patients [20]. In
Bowker’s study, it was not clear whether this increased risk is
related to a deleterious effect of insulin or a protective effect of
metformin [3]. Recently, the results of ORIGIN trial indicated
that insulin use had no effect on overall mortality in the case of
glargine insulin [12]. In our study, the overall mortality, death
from cancer, and death from pneumonia and respiratory
conditions were significantly higher in the insulin users compared
with the non-insulin users after adjustment for all potential
confounders. However, these finding might also be false positive
because of the following reasons: 1) the subjects in the insulin use
cohort were less healthy, with older age, longer diabetes duration,
poorer glucose control, and a higher percentage of microvascular
and macrovascular diseases at baseline. 2) In China, insulin is
seldom prescribed for newly diagnosed type 2 diabetic patients,
except that they exhibit extremely high levels of plasma glucose. In
general, insulin is prescribed for patients in whom OAD treatment
failed, or one or more of the following concomitant diseases are
present for which OAD treatment is contraindicated: OAD
allergy, chronic liver or renal diseases, multiple organ failure, or
some site-specific cancers. 3) The HbA1c levels were higher in the
insulin use cohort at both baseline and endpoint than in the non-
insulin use cohort, and high glucose levels may accelerate tumor
progression [21] and death [22]. 4) Other potential confounders
including hypoglycemia and weight gain or edema caused by
insulin should also be considered as factors that may have
contributed to the higher mortality risk in the insulin use cohort.
So it should be cautious to interpret the results which may be
influenced by potential confounders.
Limitations
The current study has several limitations. Firstly, the present
study was not randomized and controlled because all patients in
the two cohorts underwent drug therapy under real-world
conditions. Thus, imbalance regarding the characteristics of the
two cohorts were presented at baseline. Secondly, we were not
able to analyze the hypoglycemic events because incompleteness of
our data, and hypoglycemic events may be a major potential
confounding factor for the analysis of association between insulin
therapy and mortality risk, especially in elderly patients. Finally,
we were not able to exclude other potential confounding factors
that may have affected cancer or mortality events.
Conclusion
The present study found that insulin therapy was associated
with a higher relative risk of liver cancer, but not related with
other site-specific cancer and overall cancer risks in patients with
type 2 diabetes. Although the insulin users showed higher risks of
overall and cancer mortality than the non-insulin users in this
study, caution should be used in interpreting the results because
Table 4. Intermediate and final models with RRs (95% CIs) for insulin use (reference group: non-insulin use) for mortality.
Mortality Unadjusted
Adjusted for
age and sex
Adjusted for age,
sex, and smoking
status
Adjusted for age,
sex, smoking
status, and
diabetes
duration
Adjusted for age,
sex, smoking
status, diabetes
duration,
macrovascular,
and HbA1c
Adjusted for age,
sex, smoking
status, diabetes
duration,
macrovascular,
HbA1c, and
concomitant oral
glucose lowering
agents*
Overall mortality 2.06 (1.72–2.48) 1.85 (1.53–2.22) 1.85 (1.53–2.21) 1.77 (1.44–2.17) 1.98 (1.55–2.54) 1.89 (1.47–2.43)
Death from cancer 1.58 (1.11–2.25) 1.46 (1.02–2.08) 1.44 (1.01–2.05) 1.60 (1.11–2.31) 2.11 (1.37–3.25) 2.16 (1.39–3.35)
Death from cardiovascular
disease
2.41 (1.51–3.85) 2.02 (1.26–3.24) 2.02 (1.26–3.24) 1.92 (1.10–3.37) 1.88 (0.95–3.71) 1.83 (0.91–3.68)
Death from cerebrovascular
disease
1.61 (1.00–2.59) 1.44 (0.89–2.33) 1.43 (0.88–2.31) 1.22 (0.72–2.09) 0.89 (0.47–1.69) 0.83 (0.43–1.62)
Death from pneumonia and
respiratory failure
2.98 (1.97–4.52) 2.64 (1.73–4.01) 2.65 (1.74–4.04) 2.29 (1.43–3.67) 2.43 (1.36–4.33) 2.31 (1.27–4.18)
Death from renal failure 4.05 (1.63–10.06) 3.50 (1.40–8.74) 3.54 (1.42–8.85) 2.63 (0.94–7.30) 2.52 (0.74–8.54) 2.25 (0.63–7.95)
*Oral glucose-lowering agents, including metformin, sulfonylureas, and acarbose.
doi:10.1371/journal.pone.0053411.t004
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individuals treated with insulin were more likely to be advanced
diabetic patients. Moreover, our findings could not be directly
extrapolated to other Chinese populations and should be further
investigated and replicated in the future.
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